ASCO 2019 | Immunotherapy priming with neo-antigens

Thomas Helleday

Here, Thomas Helleday, PhD, from the University of Sheffield, Sheffield, UK, discusses the use of neo-antigens to prime tumors for immunotherapy treatment. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video